Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study

醋酸阿比特龙酯 医学 强的松 内科学 安慰剂 阉割 肿瘤科 阿比曲酮 前列腺癌 恩扎鲁胺 泌尿科 雄激素剥夺疗法 癌症 激素 病理 雄激素受体 替代医学
作者
Charles J. Ryan,Matthew R. Smith,Karim Fizazi,Fred Saad,Peter F.A. Mulders,Cora N. Sternberg,Kurt Miller,Christopher J. Logothetis,Neal D. Shore,Eric J. Small,Joan Carles,Thomas W. Flaig,Mary-Ellen Taplin,Celestia S. Higano,Paul de Souza,Johann S. de Bono,Thomas W. Griffin,Peter De Porre,Margaret K. Yu,Youn C. Park
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:16 (2): 152-160 被引量:1348
标识
DOI:10.1016/s1470-2045(14)71205-7
摘要

Background Abiraterone acetate plus prednisone significantly improved radiographic progression-free survival compared with placebo plus prednisone in men with chemotherapy-naive castration-resistant prostate cancer at the interim analyses of the COU-AA-302 trial. Here, we present the prespecified final analysis of the trial, assessing the effect of abiraterone acetate plus prednisone on overall survival, time to opiate use, and use of other subsequent therapies. Methods In this placebo-controlled, double-blind, randomised phase 3 study, 1088 asymptomatic or mildly symptomatic patients with chemotherapy-naive prostate cancer stratified by Eastern Cooperative Oncology performance status (0 vs 1) were randomly assigned with a permuted block allocation scheme via a web response system in a 1:1 ratio to receive either abiraterone acetate (1000 mg once daily) plus prednisone (5 mg twice daily; abiraterone acetate group) or placebo plus prednisone (placebo group). Coprimary endpoints were radiographic progression-free survival and overall survival analysed in the intention-to-treat population. The study is registered with ClinicalTrials.gov, number NCT00887198. Findings At a median follow-up of 49·2 months (IQR 47·0–51·8), 741 (96%) of the prespecified 773 death events for the final analysis had been observed: 354 (65%) of 546 patients in the abiraterone acetate group and 387 (71%) of 542 in the placebo group. 238 (44%) patients initially receiving prednisone alone subsequently received abiraterone acetate plus prednisone as crossover per protocol (93 patients) or as subsequent therapy (145 patients). Overall, 365 (67%) patients in the abiraterone acetate group and 435 (80%) in the placebo group received subsequent treatment with one or more approved agents. Median overall survival was significantly longer in the abiraterone acetate group than in the placebo group (34·7 months [95% CI 32·7–36·8] vs 30·3 months [28·7–33·3]; hazard ratio 0·81 [95% CI 0·70–0·93]; p=0·0033). The most common grade 3–4 adverse events of special interest were cardiac disorders (41 [8%] of 542 patients in the abiraterone acetate group vs 20 [4%] of 540 patients in the placebo group), increased alanine aminotransferase (32 [6%] vs four [<1%]), and hypertension (25 [5%] vs 17 [3%]). Interpretation In this randomised phase 3 trial with a median follow-up of more than 4 years, treatment with abiraterone acetate prolonged overall survival compared with prednisone alone by a margin that was both clinically and statistically significant. These results further support the favourable safety profile of abiraterone acetate in patients with chemotherapy-naive metastatic castration-resistant prostate cancer. Funding Janssen Research & Development.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
穆梦山完成签到,获得积分10
刚刚
Clover04的应助被籽儿采纳,获得10
刚刚
kki完成签到 ,获得积分10
刚刚
水煮电吹风的应助被卓卓卓采纳,获得10
刚刚
Akim的应助被请较老嘚采纳,获得10
刚刚
1秒前
2秒前
2秒前
2秒前
lllliiii发布了新的文献求助10
2秒前
Azumah发布了新的文献求助10
3秒前
困告发布了新的文献求助20
3秒前
3秒前
深情安青的应助被wyh2025采纳,获得10
3秒前
June发布了新的文献求助10
3秒前
方元浡发布了新的文献求助10
3秒前
4秒前
刘宇翔发布了新的文献求助30
4秒前
LV发布了新的文献求助10
5秒前
panpan完成签到,获得积分10
5秒前
蔡蔡小星完成签到,获得积分10
5秒前
害羞的灯泡完成签到,获得积分20
5秒前
yzm完成签到,获得积分10
5秒前
6秒前
7秒前
xx发布了新的文献求助10
7秒前
生动寒凝完成签到,获得积分10
7秒前
7秒前
希望天下0贩的0的应助被LV采纳,获得10
8秒前
缥缈芒果发布了新的文献求助30
8秒前
Akim的应助被蛋蛋采纳,获得10
8秒前
panpan发布了新的文献求助10
8秒前
yzm发布了新的文献求助10
8秒前
8秒前
cquank完成签到,获得积分10
8秒前
cbw发布了新的文献求助10
8秒前
机智小夏完成签到 ,获得积分10
8秒前
liuliu给liuliu的求助进行了留言
9秒前
10秒前
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181072
求助须知:如何正确求助?哪些是违规求助? 9571092
关于积分的说明 21816478
捐赠科研通 7777477
什么是DOI,文献DOI怎么找? 3433418
关于科研通互助平台的介绍 2557638
邀请新用户注册赠送积分活动 2479460